Emboline, Inc. Completes Initial Human Clinical Cases With The Emboliner Embolic Protection Catheter

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

June 5, 2018

Emboline, Inc., an emerging medical device company with a game-changing device for total embolic protection during transcatheter aortic valve replacement (TAVR) procedures, announced today the successful completion of its initial series of human clinical cases using the Emboliner Embolic Protection Catheter.

Emboline notes the initial procedures were performed at the Heart Center and the University of Dresden Hospital in Dresden, Germany as part of the SafePassTM clinical trial.

Cerebral embolism, which can lead to stroke or even death, is a known complication of TAVR. In carefully controlled studies, stroke rates related to TAVR have been shown to be as high as 27 percent.  A reliable, simple-to-use aortic embolic protection system, like the Emboliner, is critical for the adoption and growth of TAVR procedures, especially in younger, lower-risk patients.

The SafePass trial will include up to 60 patients at up to five medical centers throughout Germany, the Netherlands and Israel. The trial will assess the safety and technical performance of the Emboliner and the data will be used to submit the device for European CE Mark approval.

“Trapping and removing embolic debris during TAVR is especially critical to improving the outcomes of these procedures,” said Prof. Dr. Axel Linke, the SafePass Principal Investigator and Chairman of the Department of Internal Medicine and Cardiology at the Heart Center, University of Dresden Hospital. “We are very encouraged by the initial results we are seeing from the Emboliner device, which has captured embolic debris in every patient in the clinical cases to date. The Emboliner’s unique design, which provides full-body embolic protection, is an important addition to the field of TAVR embolic protection.”

The novel Emboliner device is intended to not only provide more reliable cerebral embolic protection, but also complete protection of the arterial bed (both cerebral and non-cerebral vessels) utilizing a uniquely ported design that maintains tool access through the filter. Providing significant improvements on first-generation TAVR embolic protection solutions, The Emboliner has been designed to offer the following potential advantages:

  • More effective coverage of all cerebral branches with fewer anatomical limitations
  • Full-body embolic protection, capturing both cerebral and non-cerebral debris
  • No requirement for an additional procedural access
  • No interference with the TAVR delivery system and accessory devices
  • An extremely user-friendly design with minimal added procedural time or complexity

“The initiation of our SafePass clinical trial will bring Emboline one step closer to achieving CE Mark approval and offering future TAVR patients a safer procedure,” said Scott Russell, Emboline’s President & CEO. “We believe that the Emboliner’s total embolic protection combined with its outstanding ease-of-use will offer physicians significant advantages over existing technologies.”



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.